Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image of neuroscience and gene therapy research, reflecting Taysha Gene Therapies’ TSHA-102 Rett syndrome update and the race to develop disease-modifying treatments for rare neurodevelopmental disorders.
Pharma & Biotech

Why Taysha’s Rett syndrome data could become a major gene therapy test case

Find out how Taysha’s TSHA-102 Rett syndrome update could shape gene therapy development, BLA planning and future disease-modifying care.

Read More
Pharma & Biotech

Regeneron’s cemdisiran enters FDA and EMA review for generalized myasthenia gravis

Find out how Regeneron’s cemdisiran review could reshape generalized myasthenia gravis care with potential quarterly subcutaneous dosing.

Read More
Representative image: Syntax Bio’s expanded Series A funding highlights growing investor interest in Cellgorithm-driven stem cell therapy for type 1 diabetes.
Pharma & Biotech

Syntax Bio funding boost puts pancreatic beta cell therapy closer to preclinical test

Find out how Syntax Bio’s expanded Series A could shape Cellgorithm-based beta cell therapy for type 1 diabetes.

Read More
Representative image: Definium Therapeutics’ DT120 ODT Phase 3 Emerge study highlights the growing focus on psychedelic psychiatry and new treatment approaches for major depressive disorder.
Pharma & Biotech

Definium Therapeutics nears pivotal MDD test as DT120 ODT faces Phase 3 scrutiny

Find out how Definium Therapeutics’ DT120 ODT Phase 3 MDD readout could reshape psychedelic psychiatry and depression drug development.

Read More
A dermatologist reviews treatment progress with a patient as MoonLake Immunotherapeutics advances sonelokimab toward an FDA filing following durable 52-week hidradenitis suppurativa results. Representative image.
Pharma & Biotech

Does sonelokimab finally justify MoonLake’s best-in-class hidradenitis suppurativa claim?

Sonelokimab delivered deeper one-year hidradenitis suppurativa responses, but MoonLake must convert cross-trial advantages into regulatory approval and commercial differentiation.

Read More
Representative image: Voro Therapeutics and Alloy Therapeutics are advancing masked T-cell engager research aimed at improving tumor-selective cancer immunotherapy.
Pharma & Biotech

Voro and Alloy target safer masked T-cell engager therapies in oncology

Find out how Voro Therapeutics and Alloy Therapeutics aim to advance safer masked T-cell engager cancer therapies.

Read More
Representative image: Laboratory research on macrophage-targeted therapies highlights 101 Therapeutics’ push for independent review of 101-PGC-005 in Bundibugyo Ebola disease.
Pharma & Biotech

Can 101 Therapeutics’ macrophage-targeting approach change the race for a Bundibugyo Ebola treatment?

101 Therapeutics has released new data on 101-PGC-005 for Bundibugyo Ebola disease. Discover what it could mean for outbreak response and drug development.

Read More
Representative image: AI-driven protein design in a modern biotech lab, reflecting Chai Discovery’s Lilly TuneLab collaboration to expand miniprotein discovery tools for select biotechs.
Pharma & Biotech

Chai Discovery tests a new commercial route for AI-designed biologics through Lilly TuneLab

Explore how Chai Discovery and Lilly TuneLab are widening biotech access to AI miniprotein design and what must happen next.

Read More
Researchers review targeted cancer-therapy data as Veraxa Biotech develops its BiTAC-ADC platform to improve tumour selectivity and reduce off-target toxicity in antibody-drug conjugates. Representative image.
Pharma & Biotech

Why Veraxa Biotech stock fell 23% after its BiTAC-ADC proof-of-concept data

Veraxa Biotech’s split-component antibody-drug conjugate platform could reduce off-tumour toxicity, but investors received laboratory evidence rather than the clinical roadmap needed to support its newly public valuation.

Read More
Biopharma executives review acquisition documents as AbbVie reportedly nears a $10.9 billion deal for Apogee Therapeutics and its Phase 3-ready eczema drug zumilokibart. Representative image.
Pharma & Biotech

AbbVie nears reported $10.9bn Apogee deal as zumilokibart heads toward Phase 3

AbbVie could pay a substantial premium for Apogee Therapeutics and its long-acting eczema antibody, but the reported deal depends on Phase 3 success and differentiation from established immunology drugs.

Read More